Eli Lilly and Co. (LLY) Stock Rating Reaffirmed by Jefferies Group
Several other equities research analysts have also issued reports on LLY. Credit Suisse Group AG reissued a buy rating on shares of Eli Lilly and in a research report on Thursday, May 26th. TheStreet raised Eli Lilly and from a hold rating to a buy rating in a research report on Friday, May 27th. Morgan Stanley reissued a hold rating and set a $88.00 price target on shares of Eli Lilly and in a research report on Saturday, June 4th. SunTrust Banks Inc. reissued a buy rating on shares of Eli Lilly and in a research report on Wednesday, June 15th. Finally, Leerink Swann reaffirmed a buy rating on shares of Eli Lilly and in a research report on Sunday, June 26th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $96.85.
Eli Lilly and (NYSE:LLY) opened at 79.16 on Wednesday. The firm has a market cap of $83.73 billion, a P/E ratio of 34.12 and a beta of 0.20. Eli Lilly and has a 1-year low of $67.88 and a 1-year high of $88.48. The stock’s 50 day moving average price is $79.61 and its 200 day moving average price is $76.71.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. The business had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.90 EPS. Equities research analysts predict that Eli Lilly and will post $3.59 EPS for the current year.
In other Eli Lilly and news, Director Jackson P. Tai bought 2,560 shares of the stock in a transaction on Friday, August 12th. The shares were purchased at an average price of $80.42 per share, with a total value of $205,875.20. Following the acquisition, the director now directly owns 42,110 shares of the company’s stock, valued at approximately $3,386,486.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jackson P. Tai bought 5,773 shares of the stock in a transaction on Monday, August 15th. The stock was acquired at an average cost of $80.43 per share, for a total transaction of $464,322.39. Following the acquisition, the director now directly owns 42,306 shares in the company, valued at $3,402,671.58. The disclosure for this purchase can be found here. 0.20% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. raised its stake in Eli Lilly and by 0.4% in the second quarter. Macquarie Group Ltd. now owns 426,150 shares of the company’s stock worth $33,560,000 after buying an additional 1,700 shares during the period. Carnick & Kubik Group LLC acquired a new stake in Eli Lilly and during the second quarter worth about $686,000. Williams Jones & Associates LLC raised its stake in Eli Lilly and by 341.1% in the second quarter. Williams Jones & Associates LLC now owns 12,130 shares of the company’s stock worth $955,000 after buying an additional 9,380 shares during the period. Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in Eli Lilly and during the second quarter worth about $3,089,000. Finally, Kentucky Retirement Systems acquired a new stake in Eli Lilly and during the second quarter worth about $6,505,000. 75.06% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.